Campbell Newman Asset Management Inc Bristol Myers Squibb CO Transaction History

Campbell Newman Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$48.48 - $57.85 $720,849 - $860,171	-14,869 Reduced 45.3%	17,957 $921,000
Q2 2021 Jul 16, 2021	SELL	$61.91 - $67.42 $417,892 - $455,085	-6,750 Reduced 17.06%	32,826 $2.19 Million
Q1 2021 Apr 19, 2021	SELL	$59.34 - $66.74 $10.7 Million - $12 Million	-180,444 Reduced 82.01%	39,576 $2.5 Million
Q4 2020 Feb 01, 2021	BUY	$57.74 - $65.43 $652,866 - $739,817	11,307 Added 5.42%	220,020 $13.6 Million
Q3 2020 Oct 20, 2020	BUY	$57.43 - $63.64 $83,962 - $93,041	1,462 Added 0.71%	208,713 $12.6 Million
Q2 2020 Jul 27, 2020	BUY	$54.82 - $64.09 $4.39 Million - $5.13 Million	80,008 Added 62.88%	207,251 $12.2 Million
Q1 2020 Apr 27, 2020	BUY	$46.4 - $67.43 $33,686 - $48,954	726 Added 0.57%	127,243 $7.09 Million
Q4 2019 Jan 22, 2020	BUY	$49.21 - $64.19 $4.64 Million - $6.06 Million	94,378 Added 293.66%	126,517 $8.12 Million
Q1 2018 Apr 25, 2018	SELL	$59.92 - $68.98 $138,415 - $159,343	-2,310 Reduced 6.71%	32,139 $2.03 Million
Q3 2017 Oct 11, 2017	SELL	$55.23 - $63.74 $46,945 - $54,179	-850 Reduced 2.41%	34,449 $2.2 Million
Q2 2017 Aug 09, 2017	BUY	N/A	35,299	35,299 $1.97 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Campbell Newman Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Campbell Newman Asset Management Inc with notifications on news.